Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) Treated with Pediatric Argentine BFM-like Protocol: Real-Word Data on Prognostic Factors and Treatment

Blood (2021) 138 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2021-151448

Published: 2021

Journal Articles

High Level of Successful TKI Discontinuation in Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of AST-Argentina Stop Trial

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-142416

Published: 2020

Journal Articles

Real World Efficacy Evaluation of Branded and Copy Imatinib in Chronic Myeloid Leukemia: A Retrospective Multicentric Study from Argentina

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137792

Published: 2020

Journal Articles

In Pursuit of Surrogate Markers for Treatment-Free Remission in Patients with Chronic Myeloid Leukemia from Argentina Stop Trial

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-141067

Published: 2020

Journal Articles

Impact on Quality of Life (QoL) of Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Under Ibrutinib Treatment: Preliminary Data from a Real World Prospective Project (pilot study)

Maria J. Mela Osorio, MD, Carolina Pavlovsky, MD, Mariana Juni, Ms, Isolda I. Fernandez, MD, Luciana C. Ferrari, MD, Esteban Ciliberti, MD, Miguel A. Pavlovsky, MD

Blood (2017) 130 (Supplement 1): 5343.

https://doi.org/10.1182/blood.V130.Suppl_1.5343.5343

Published: 2017

Journal Articles

Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review

Miguel A. Pavlovsky, MD, Kavita Sail, PhD, Leonardo Passos Chaves, MD MSc, Rajesh Kamalakar, MS, Xiaojing Ma, MS, Patricia Brandalise, MD MSC, Carlos Chiattone, MD

Blood (2017) 130 (Supplement 1): 5617.

https://doi.org/10.1182/blood.V130.Suppl_1.5617.5617

Published: 2017

Journal Articles

A Retrospective Multicenter Analysis of the Safety and Efficacy of Brentuximab Vedotin (BV) As Monotherapy or in Combination with Bendamustine (BV-B) in Relapsed Refractory Classic Hodgkin Lymphoma (cHL) in Argentina

Florencia Negri Aranguren, MD, Santiago Cranco, Claudia Shanley, MD, Isolda I. Fernandez, MD, Maria Virginia Prates, MD, Victoria Otero, Lorena Fiad, Maria Cecilia Foncuberta, MD, Marcela Miodosky, MD, Miguel A. Pavlovsky, MD, Gustavo Kuminsky, Javier Bordone, Bruno Wannesson, Ariel Corso Corso, Dardo Riveros, MD, Marisa Marquez, MD, Gustavo Jarchum, MD, Maria Sol Jarchum, Ider Ramon Cerutti, MD, Alicia Bistmas, Monica Tamashiro, MD, Giselda De Stefano, Alicia Navieckas, Silvana Cugliari, MD, Pedro Negri Aranguren, MD, Gabriela Balaguer, Maria Tosin, Guillermina Remaggi, Juan Altuve, Juan Jose Garcia, MD, Luciana C. Ferrari, MD, Graciela Klein, Luciana Guanchiale, Luis Beligoy, MD, Mariana Marull, Maria Cecilia Dacunto, Marta Elisa Zerga, MD, Nicolas Matias Kurgansky, MD, Marcelo Pujol, MD, Rossana L. Taus, MD PhD, Federico Sackman, MD PhD, Veronica Cintia Canosa, Soledad Cruset, Maximiliano Riddick, Astrid Pavlovsky, MD

Blood (2017) 130 (Supplement 1): 4089.

https://doi.org/10.1182/blood.V130.Suppl_1.4089.4089

Published: 2017

Journal Articles

Results from a Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with NHL

Miguel A Pavlovsky, MD, Laura Fogliatto, MD, Gladys Patricia Agreda Vásquez, MD, Alicia Enrico, MD, María Jose Mela Osorio, MD, Jorge Antonio Armenta San-Sebastian, MD, Roberto Ovilla, MD PhD, Oscar Avendaño, MD, Lineth López, MD, Telma Santos, MD PhD, Odin De La Mora Estrada, MD

Blood (2016) 128 (22): 5327.

https://doi.org/10.1182/blood.V128.22.5327.5327

Published: 2016

Journal Articles

"M3-M6" Molecular Response Evolution As Early Predictor of Outcome Considering Generic Vs Branded TKIs for Chronic Myeloid Leukemia (CML): An Argentine Multicentric Study

Isabel Amanda Giere, PhD M.Sc, María Jose Mela Osorio, MD, Federico Andrés Klosowski, Mariana Debus, Federico Sackmann, MD, Miguel A Pavlovsky, MD, Isolda Fernandez, MD, Elena Beatriz Moiraghi, MD, Ana Inés Varela, MD, Mariel Ana Perez, MD, Julio M. Pose Cabarcos, MD, Georgina Bendek, MD, Romina Mariano, MD, Silvina Palmer, MD, Alicia Enrico, MD, Isabel Cristina Annetta, MD, Andres L. Brodsky, MD PhD, Dante Intile, Statistic MD, Carolina Pavlovsky, MD

Blood (2016) 128 (22): 5445.

https://doi.org/10.1182/blood.V128.22.5445.5445

Published: 2016

Journal Articles

Real-World Data from Long Term Follow-up in Chronic Myeloid Leukemia (CML) Patients (PTS) Treated with Imatinib. Predictive Factors for Achievement of Deep Molecular Responses and for Failure

María Jose Mela Osorio, MD, Isabel Amanda Giere, PhD M.Sc, Isolda Fernandez, MD, Miguel A Pavlovsky, MD, Guillermina Remaggi, MD, Federico Sackmann, Dante Intile, Statistic, Carolina Pavlovsky, MD

Blood (2015) 126 (23): 5169.

https://doi.org/10.1182/blood.V126.23.5169.5169

Published: 2015

Journal Articles

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Ana Inés Varela, MD, Romina Laura Penalba, Alicia Enrico, MD, Marta Catalan, Maria Veronica Ventriglia, Maria Josefina Freitas, Carolina Pavlovsky, MD, Susana Garbiero, PhD, Martin Beccasese, MD, Raquel Maria Nelida Bengio, MD, Catalina Abramovich, MD, Miguel A Pavlovsky, MD, Elena Beatriz Moiraghi, MD

Blood (2015) 126 (23): 5149.

https://doi.org/10.1182/blood.V126.23.5149.5149

Published: 2015

Journal Articles

Chronic Myeloid Leukemia (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study

Isabel Amanda Giere, PhD M.Sc, María Jose Mela Osorio, MD, Federico Andrés Klosowski, Mariana Debus, Ana Inés Varela, MD, Elena Beatriz Moiraghi, MD, Miguel A Pavlovsky, MD, Isolda Fernandez, MD, Dante Intile, Statistic, Carolina Pavlovsky, MD

Blood (2015) 126 (23): 1590.

https://doi.org/10.1182/blood.V126.23.1590.1590

Published: 2015

Journal Articles

Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience

Carolina Pavlovsky, MD, Isolda Fernandez, MD, Miguel A Pavlovsky, MD, Adriana Galeano, Federico Sackmann, Dante Intile, Statistic, Astrid Pavlovsky, MD

Blood (2015) 126 (23): 1739.

https://doi.org/10.1182/blood.V126.23.1739.1739

Published: 2015

Journal Articles

Therapeutic Approach to Advanced Follicular Lymphoma at Diagnosis: An Argentinian Survey

Blood (2014) 124 (21): 4408.

https://doi.org/10.1182/blood.V124.21.4408.4408

Published: 2014

Journal Articles

Ruxolitinib In Myelofibrosis (MF) Patients Through Compassionate Use Program (CUP). Argentinian Experience

Blood (2013) 122 (21): 5247.

https://doi.org/10.1182/blood.V122.21.5247.5247

Published: 2013

Journal Articles

PET -CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Preliminary Results in 193 Patients

Astrid Pavlovsky, Isolda Fernandez, Virginia Prates, Miguel A Pavlovsky, Lucia Zoppegno, Ana Lisa Basquiera, Federico Sackmann, Francisco Lastiri, Gustavo Milone, Santiago Pavlovsky

Blood (2011) 118 (21): 1619.

https://doi.org/10.1182/blood.V118.21.1619.1619

Published: 2011

Journal Articles

Evaluation of Prognostic Factors for Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance

Federico Sackmann, Claudia Corrado, Isolda Fernandez, Miguel A Pavlovsky, Pablo Mountford, Astrid Pavlovsky, Miguel Pavlovsky, Mariel Alejandre, Marco Pizzolato, Santiago Pavlovsky, MD, PhD

Blood (2008) 112 (11): 5123.

https://doi.org/10.1182/blood.V112.11.5123.5123

Published: 2008

Journal Articles

Prospective Evaluation of the International Prognostic Score (IPS) in All Stages of Hodgkin’s Lymphoma Treated with ABVD Plus Involved-Field Radiotherapy (IFRT).

Santiago Pavlovsky, Claudia Corrado, Miguel A Pavlovsky, Virginia Prates, Lucia Zoppegno, Mario Giunta, Ider Cerutti, Elsa Palomino, Graciela Avila, Francisco Lastiri

Blood (2008) 112 (11): 1454.

https://doi.org/10.1182/blood.V112.11.1454.1454

Published: 2008

Journal Articles

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Carolina Pavlovsky, MD, Santiago Pavlovsky, MD PhD, Maria L. Pardo, MD, Sandra Sapia, MD, Mariela Monreal, MD, Claudia Corrado, MDd, Miguel A. Pavlovsky, MD, Isolda Fernandez, MD, Mariana Juni, MS

Blood (2006) 108 (11): 4968.

https://doi.org/10.1182/blood.V108.11.4968.4968

Published: 2006

Journal Articles

Monitoring Response to Imatinib by Fluorescence In Situ Hybridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase. Experience of Argentina and Uruguay.

Blood (2006) 108 (11): 4766.

https://doi.org/10.1182/blood.V108.11.4766.4766

Published: 2006

NARROW

Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) Treated with Pediatric Argentine BFM-like Protocol: Real-Word Data on Prognostic Factors and Treatment

High Level of Successful TKI Discontinuation in Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of AST-Argentina Stop Trial

Real World Efficacy Evaluation of Branded and Copy Imatinib in Chronic Myeloid Leukemia: A Retrospective Multicentric Study from Argentina

In Pursuit of Surrogate Markers for Treatment-Free Remission in Patients with Chronic Myeloid Leukemia from Argentina Stop Trial

Impact on Quality of Life (QoL) of Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Under Ibrutinib Treatment: Preliminary Data from a Real World Prospective Project (pilot study)

Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review

A Retrospective Multicenter Analysis of the Safety and Efficacy of Brentuximab Vedotin (BV) As Monotherapy or in Combination with Bendamustine (BV-B) in Relapsed Refractory Classic Hodgkin Lymphoma (cHL) in Argentina

Results from a Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with NHL

"M3-M6" Molecular Response Evolution As Early Predictor of Outcome Considering Generic Vs Branded TKIs for Chronic Myeloid Leukemia (CML): An Argentine Multicentric Study

Real-World Data from Long Term Follow-up in Chronic Myeloid Leukemia (CML) Patients (PTS) Treated with Imatinib. Predictive Factors for Achievement of Deep Molecular Responses and for Failure

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Chronic Myeloid Leukemia (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study

Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience

Therapeutic Approach to Advanced Follicular Lymphoma at Diagnosis: An Argentinian Survey

Ruxolitinib In Myelofibrosis (MF) Patients Through Compassionate Use Program (CUP). Argentinian Experience

PET -CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Preliminary Results in 193 Patients

Evaluation of Prognostic Factors for Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance

Prospective Evaluation of the International Prognostic Score (IPS) in All Stages of Hodgkin’s Lymphoma Treated with ABVD Plus Involved-Field Radiotherapy (IFRT).

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Monitoring Response to Imatinib by Fluorescence In Situ Hybridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase. Experience of Argentina and Uruguay.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only